// App-Quantinova.ai

753 : C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials

Researchers

Presenter

  • Raymond S Wong

Principal Investigators

  • Kalina Ignatova

  • Humphrey Pullon

  • Jameela Sathar

  • Pimjai Niparuck

  • Tontanai Numbenjapon

  • Eric Tse

  • Surapol Issaragrisil

  • Eloy Roman

  • Ismail Amine

  • Lisa Tan

  • Carl Di Casoli

  • Pascal Deschatelets

  • Cedric Francois

  • Federico Grossi

  • Andrija Bogdanovic

Medical Centers

  • Sir YK Pao Centre for Cancer & Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong

  • University National Specialised Hospital for Active Treatment of Haematological Diseases,Sofia,Bulgaria

  • Waikato Hospital, Hamilton, New Zealand

  • Department of Haematology, Ampang Hospital, Selangor, Malaysia

  • Ramathibodi Hospital, Bangkok, Thailand

  • Phramongkutklao College of Medicine Bangkok Thailand

  • Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

  • Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand

  • Lakes Research, Miami Lakes, FL

  • Lisa Tan Pharma Consulting, Cambridge, United Kingdom

  • AMAG Pharmaceuticals, Inc., Waltham, MA

  • Department of Cardiology, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Locations

  • Hong Kong

  • Bulgaria

  • New Zealand

  • Malaysia

  • Thailand

  • United States

  • United Kingdom

  • Serbia

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Open Label

  • Cohort

Phase

  • II

Study Id's

  • NCT02588833

  • NCT03593200

  • NCT04085601

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved